Review Article
Year: 2023 | Month: September | Volume: 13 | Issue: 9 | Pages: 48-52
DOI: https://doi.org/10.52403/ijhsr.20230909
A Review of the Role of Canakinumab - An Anti-Inflammatory Agent in CAD
Temitope Olayinka1, Chiugo Okoye2, Oham Amarachi3, Iyah Victory4, Olawale Ajayi5, Chisom Obika6, Omosalewa Koya7
1College of Public Health, Kent State University, Kent, Ohio, United States of America
2Department of Medicine, Igbinedion University Okada, Edo State, Nigeria
3Department of Medicine, Greater Accra Regional Hospital, North Ridge, Accra Ghana
4Department of Medicine, Irrua Specialist Teaching Hospital Edo State, Nigeria
5Department of Medicine, Orile Agege General Hospital, Lagos State, Nigeria
6Department of Medicine, College of Medicine, University of Nigeria, Enugu
7Department of Medicine, Cedar Crest Hospital, Abuja, Nigeria
Corresponding Author: Chiugo Okoye
ABSTRACT
Coronary Artery Disease (CAD) is the leading cause of mortality and loss of disability-adjusted life years (DALYs) worldwide. Optimal medical therapy is the cornerstone of management for patients with CAD. However, patients on currently available medical therapy still have a residual risk of poor cardiovascular outcomes. Recent studies have underscored the role of inflammation in the development and progression of CAD and proposed that anti-inflammatories such as Canakinumab may significantly reduce the incidence of poor cardiovascular outcomes. This review explored the role of Canakinumab in CAD management and discovered that Canakinumab without the requirement of daily dosing, reduces the incidence of adverse cardiovascular outcomes in CAD patients. However, its high cost and limited knowledge concerning its long-term effects may limit its use for CAD patients
Key words: Canakinumab, Coronary artery disease, Inflammation. Anti-inflammatory, Cardiovascular management, pharmacology